Andreas Karagiannis1, John Varkarakis2. 1. Department of Urology, Athens Euroclinic Hospital, 7-9 Athanasiadou & D. Soutsou str., 151 21, Athens, Greece. andreaskaragiannis@gmail.com. 2. Department of Urology, School of Medicine, Sismanogleio Hospital, National and Kapodistrian University of Athens, Sismanogleiou 1 str., 15126, Marousi, Athens, Greece.
Abstract
PURPOSE OF REVIEW: Although still considered experimental, focal irreversible electroporation (IRE) as a primary treatment for prostate cancer (PCa) is considered one of the most promising ablative technologies for focal therapy. This review provides a description of the principle of IRE for the treatment of PCa, combined with an overview of the recent research. RECENT FINDINGS: It has been almost a decade since the first human studies of focal IRE for PCa were trying to demonstrate its feasibility and safety, and recently new data are emerging regarding the functional and oncological outcomes. It was shown that the expected ablation efficacy of IRE is dependent on increased safety margins of > 9 mm and an uninterrupted IRE procedure, but these findings need further investigation in larger cohorts and randomized control trials (RCT). Recent data from larger cohorts with a longer follow-up of up to 12 months prove that focal IRE as primary treatment for localized PCa is indeed safe, has effective short-term oncological control in selected patients, and it has good functional outcomes by retaining urinary function and causing only mild erectile dysfunction.
PURPOSE OF REVIEW: Although still considered experimental, focal irreversible electroporation (IRE) as a primary treatment for prostate cancer (PCa) is considered one of the most promising ablative technologies for focal therapy. This review provides a description of the principle of IRE for the treatment of PCa, combined with an overview of the recent research. RECENT FINDINGS: It has been almost a decade since the first human studies of focal IRE for PCa were trying to demonstrate its feasibility and safety, and recently new data are emerging regarding the functional and oncological outcomes. It was shown that the expected ablation efficacy of IRE is dependent on increased safety margins of > 9 mm and an uninterrupted IRE procedure, but these findings need further investigation in larger cohorts and randomized control trials (RCT). Recent data from larger cohorts with a longer follow-up of up to 12 months prove that focal IRE as primary treatment for localized PCa is indeed safe, has effective short-term oncological control in selected patients, and it has good functional outcomes by retaining urinary function and causing only mild erectile dysfunction.
Authors: Hester J Scheffer; Karin Nielsen; Marcus C de Jong; Aukje A J M van Tilborg; Jenny M Vieveen; Arthur R A Bouwman; Sybren Meijer; Cornelis van Kuijk; Petrousjka M P van den Tol; Martijn R Meijerink Journal: J Vasc Interv Radiol Date: 2014-03-18 Impact factor: 3.464
Authors: Matthijs J Scheltema; John I Chang; Maret Böhm; Willemien van den Bos; Alexandar Blazevski; Ilan Gielchinsky; Anton M F Kalsbeek; Pim J van Leeuwen; Tuan V Nguyen; Theo M de Reijke; Amila R Siriwardana; James E Thompson; Jean J de la Rosette; Phillip D Stricker Journal: World J Urol Date: 2018-03-28 Impact factor: 4.226
Authors: Alex Z Wang; Amir H Lebastchi; Luke P O'Connor; Michael Ahdoot; Sherif Mehralivand; Nitin Yerram; Samir S Taneja; Arvin K George; Rafael Sanchez-Salas; John F Ward; Pilar Laguna; Jean de la Rosette; Peter A Pinto Journal: World J Urol Date: 2021-01-02 Impact factor: 4.226
Authors: Giuseppe Fallara; Paolo Capogrosso; Paolo Maggio; Alessandro Taborelli; Francesco Montorsi; Federico Dehò; Andrea Salonia Journal: Int J Impot Res Date: 2020-09-30 Impact factor: 2.896